Nona Biosciences, a biotechnology company providing a total solution from “Idea to IND” (I to I™), ranging from target validation and antibody discovery through preclinical research, has entered into an exclusive license agreement with Pfizer for the global clinical development and commercialization of HBM9033, Nona Biosciences’ MSLN-targeted antibody-drug conjugate (ADC).

HBM9033 is an ADC drug candidate that specifically targets human mesothelin (MSLN), an upregulated tumor associated antigen (TAA) in various solid tumors, including mesothelioma, ovary cancer, lung cancer, breast cancer, and pancreatic cancers. MSLN is considered an attractive therapeutic target for ADCs because of significant differences in expression pattern between diseased and normal tissues.

The fully human monoclonal antibody in HBM9033 is derived from the Harbour Mice® platform* and possesses well-tuned properties, exhibiting reduced binding to shedding MSLN (sMSLN) while maintaining strong binding and internalization to membrane-bound MSLN. The unique design of the antibody ensures superior potency and safety in various preclinical tumor models with differing MSLN expression levels, positioning HBM9033 as a potential globally best-in-class therapeutic option.

Under the terms of the agreement, Nona Biosciences, a wholly-owned subsidiary of HBM Holdings, receives up to US $ 53 million in upfront and near-term payments, with the potential for additional payments of up to $1.05 billion upon achieving certain development and commercial milestones. Nona Biosciences is also eligible to receive tiered royalties on net sales ranging from high single digits to high teens.

Advertisement #3 
Lonza 2024

“We are delighted to collaborate with Pfizer, a company that is committed to developing high-impact medicines for people living with cancer,” noted Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences.

“This agreement represents a significant milestone in the advancement of our proprietary Harbour Mice® platform and the ADC ecosystem, affirming Nona’s robust capabilities and expertise in antibody discovery and development. This partnership with Pfizer further enhances Nona’s global network of collaborations through innovative models, thereby amplifying the scientific and commercial value of our technology platforms.”


Note: * Harbour Mice® generate fully human monoclonal antibodies in a traditional two heavy and two light chain (H2L2) format, and a heavy chain only (HCAb) format.

Advertisement #4